**Amendments to the Claims:**

This listing of claims replaces all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A compound represented by Formula I:




I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl ~~or naphthyl~~;

m = 0 or 1;

n = 0 or 1;

**A** is ~~selected from the group consisting of: $-CO_2H$, $-PO_3H_2$, $-PO_2H$, $-SO_3H$, $-PO(C_1$-$_3$alkyl)OH and 1*H*-tetrazol-5-yl~~;

$R^1$ and $R^2$ are each independently selected from the group consisting of: hydrogen~~, halo, hydroxy, $-CO_2H$~~ and $C_1$-$_4$alkyl~~, optionally substituted from one up to the maximum number of substitutable positions with halo~~;

$R^3$ is selected from the group consisting of: hydrogen and $C_1$-$_4$alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;

each $R^4$ is independently selected from the group consisting of: halo, $C_1$-4alkyl and $C_1$-3alkoxy, said $C_1$-4alkyl and $C_1$-3alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo,

**C** is ~~selected from the group consisting of:~~

~~(1) $C_{1-8}$alkyl, $C_{1-8}$alkoxy, -(C=O)-$C_{1-6}$alkyl or -CHOH-$C_{1-6}$alkyl, said $C_{1-8}$alkyl, $C_{1-8}$alkoxy, -(C=O)-$C_{1-6}$alkyl and -CHOH-$C_{1-6}$alkyl optionally substituted with phenyl, and~~

~~(2) phenyl or~~ HET, wherein HET is thienyl, ~~each~~ optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl[[,]] and $C_1$-4alkyl ~~and $C_1$-4alkoxy~~, said $C_1$-4alkyl ~~and $C_1$-4alkoxy groups~~ optionally substituted from one up to the maximum number of substitutable positions with ~~a substituent independently selected from~~ halo ~~and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo and $C_{1-4}$alkyl, optionally substituted with 1-3 halo groups,~~

~~or **C** is not present~~; and

~~when **C** is not present then **B** is selected from the group consisting of: phenyl, $C_5$-16alkyl, $C_5$-16alkenyl, $C_5$-16alkynyl, -CHOH-$C_4$-15alkyl, -CHOH-$C_4$-15alkenyl, -CHOH-$C_4$-15alkynyl, $C_{4-15}$alkoxy, -O-$C_4$-15alkenyl, -O-$C_4$-15alkynyl, $C_4$-15alkylthio, -S-$C_4$-15alkenyl, -S-$C_4$-15alkynyl, -$CH_2$-$C_3$-14alkoxy, -$CH_2$-O-$C_3$-14alkenyl, -$CH_2$-O-$C_3$-14alkynyl, -(C=O)-$C_4$-15alkyl, -(C=O)-$C_4$-15alkenyl, -(C=O)-$C_4$-15alkynyl, -(C=O)-O-$C_3$-14alkyl, -(C=O)-O-$C_3$-14alkenyl, -(C=O)-O-$C_3$-14alkynyl, -(C=O)-N($R^6$)($R^7$)-$C_3$-14alkyl, -(C=O)-N($R^6$)($R^7$)-$C_3$-14alkenyl, -(C=O)-N($R^6$)($R^7$)-$C_3$-14alkynyl, -N($R^6$)($R^7$)-(C=O)-$C_3$-14alkyl, -N($R^6$)($R^7$)-(C=O)-$C_3$-14alkenyl and -N($R^6$)($R^7$)-(C=O)-$C_3$-14alkynyl,~~

~~when **C** is phenyl or HET then~~ **B** is ~~selected from the group consisting of: $C_1$-6alkyl,~~ $C_1$-5alkoxy~~, -(C=O)-$C_1$-5alkyl, -(C=O)-O-$C_1$-4alkyl, -(C=O)-N($R^6$)($R^7$)-$C_1$-4alkyl,~~




~~, phenyl and HET, and~~

~~when **C** is $C_{1-8}$alkyl, $C_{1-8}$alkoxy, -(C=O)-$C_{1-6}$alkyl or -CHOH-$C_{1-6}$alkyl then **B** is phenyl; and~~

~~$R^6$ and $R^7$ are independently selected from the group consisting of: hydrogen, $C_{1-9}$alkyl and -$(CH_2)_p$-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: $C_{1-3}$alkyl and $C_{1-3}$alkoxy, each optionally substituted with 1-3 halo groups.~~

2. (currently amended) The compound according to Claim 1 wherein:

~~Ar is phenyl;~~

the group ~~–~~**B**-**C** is attached to the phenyl ring at the 3- or 4-position~~;~~

~~**C** is phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, $C_{1-4}$alkyl and $C_{1-4}$alkoxy, said $C_{1-4}$alkyl and $C_{1-4}$alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of : halo and $C_{1-4}$alkyl, optionally substituted with 1-3 halo groups,~~

~~or **C** is not present;~~

~~when **C** is not present then **B** is selected from the group consisting of: $C_{7-12}$alkyl, $C_{7-12}$alkenyl, $C_{7-12}$alkynyl, $C_{6-11}$alkoxy, -O-$C_{6-11}$alkenyl, -O-$C_{6-11}$alkynyl, -(C=O)-$C_{6-11}$alkyl, -(C=O)-~~

~~$C_{6-11}$alkenyl, (C=O) $C_{6-11}$alkynyl, (C=O) O $C_{5-10}$alkyl, (C=O) O $C_{5-19}$alkenyl, and (C=O) O $C_{5-10}$alkynyl and **C** is not present;~~

~~and~~

~~when **C** is phenyl or HET then **B** is selected from the group consisting of $C_1$-5alkyl, $C_{1-4}$alkoxy, (C=O) $C_{1-4}$alkyl, (C=O) O $C_{1-3}$alkyl, phenyl and HET~~.

3. (canceled)

4. (original) The compound according to Claim 1 wherein m is 0.

5. (original) The compound according to Claim 1 wherein m is 1.

6. (original) The compound according to Claim 1 wherein n is 0.

7. (original) The compound according to Claim 1 wherein n is 1.

8. (canceled)

9. (currently amended) The compound according to Claim 1 wherein:

**B** is methoxy and **C** is HET, wherein said HET is thienyl substituted with phenyl and $C_1$-4alkyl, said $C_1$-4alkyl optionally substituted from one up to the maximum number of substitutable positions with halo~~, and said phenyl, optionally substituted with 1 to 5 substituents independently selected from the group consisting of: halo and $C_{1-4}$alkyl, optionally substituted with 1-3 halo groups~~.

10 to 20. (canceled)

21. (currently amended) The compound according to Claim ~~20~~ 4 wherein $R^1$, $R^2$ and $R^3$ are hydrogen.

22. (original) The compound according to Claim 2 wherein the group **–B-C** is attached to the phenyl ring at the 4-position.

23. (canceled)

24. (original) A compound represented by Formula II




II

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

n = 0 or 1;

$R^3$ is selected from the group consisting of: hydrogen and $C_{1-4}$alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;

each $R^4$ is independently selected from the group consisting of: halo, $C_1$-4alkyl and $C_1$-3alkoxy, said $C_1$-4alkyl and $C_1$-3alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo.

25. (original) The compound according to Claim 24 wherein n is 0.

26. (original) The compound according to Claim 24 wherein n is 1.

27. (original) The compound according to Claim 24 wherein $R^3$ is hydrogen.

28. (currently amended) The compound according to Claim 24 selected from the following table:





or a pharmaceutically acceptable salt of any of the foregoing compounds.

29 to 33. (canceled)

34. (withdrawn) A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

35 to 47. (canceled)